Satraplatin has been primarily studied in the treatment of prostate cancer, especially in cases where the disease is resistant to hormone therapy. Research has also explored its potential use in other cancers such as ovarian, lung, and small cell lung cancer. However, its most significant impact has been observed in the context of hormone-refractory prostate cancer.
